Target Genome Modification Technology Receives US Patent
- Full Circles
- Mar 7
- 1 min read
Full Circles Therapeutics announced that the United States Patent and Trademark Office (USPTO) has allowed its foundational patent titled "Targeted Genome Modification Using Circular Single-Stranded Dna." This patent protects Full Circles' innovative platform, which enables precise, efficient, and non-viral genome modification using circular single-stranded DNA (cssDNA), overcoming key challenges in genome engineering.
This breakthrough provides a safer, modular, and scalable alternative to viral vectors and traditional double-stranded DNA (dsDNA) donors, improving gene integration efficiency while minimizing immunogenicity, cytotoxicity, and off-target effects. With broad applications in cell and gene therapy, regenerative medicine, and biomedical research, this platform is poised to transform the field of genetic modification.
The growing demand for safe and efficient genome editing technologies has highlighted the limitations of viral-based gene transfer methods, such as lentiviral and adeno-associated virus (AAV) vectors, which present risks of unpredictable genomic integration, immunogenicity, and manufacturing challenges.
Full Circles' cssDNA-based technology, dubbed C4DNA™ GATALYST™ genome engineering platform, enables targeted transgene integration via homology-directed repair (HDR) without the risks of viral vectors, improving precision while reducing toxicity. This makes it ideal for next-generation, virus-free therapeutic applications.
"The allowance of this patent is a significant milestone in advancing non-viral genome editing," said Richard Shan, co-founder and Chairman of Full Circles Therapeutics. "Our proprietary cssDNA platform offers a safer and more precise alternative for gene modification, paving the way for improved allogeneic cell therapies, CAR-NK and CAR-T therapies, and other transformative treatments."